Analysts think LXEO stock price could increase by 951%
Apr 15, 2025, 11:25 AM
24.82%
What does LXEO do
Lexeo Therapeutics, a New York City-based genetic medicine company, focuses on therapies for hereditary and acquired diseases and recently went public on November 3, 2023. Its pipeline includes cardiovascular candidates LX2006 and LX2020, both undergoing clinical evaluation.
8 analysts think LXEO stock price will increase by 951.05%. The current median analyst target is $22.44 compared to a current stock price of $2.13. The lowest analysts target is $16.16 and the highest analyst target is $29.40.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
